Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | PTPRF | P10586 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788225 | 0.86 | NR3C1 (0.56) | NR3C1HTTKEAP1NFE2L2TP53 | |
| SCHEMBL2034374 | 0.86 | NR3C1 (0.56) | NR3C1HTTKEAP1NFE2L2TP53 | |
| SCHEMBL16759968 | 0.79 | KEAP1 (0.61) | NR3C1SMN1; SMN2KEAP1NFE2L2CA12 | |
| SCHEMBL29788215 | 0.79 | KEAP1 (0.61) | NR3C1SMN1; SMN2KEAP1NFE2L2CA12 | |
| SCHEMBL3207018 | 0.78 | MAPT (0.49) | HTTKDM4EPOLBTP53MAPT | |
| SCHEMBL6888946 | 0.77 | EGFR (0.57) | KDM4EPOLBPTPRCPTPRFPTPN1 | |
| SCHEMBL5227771 | 0.77 | FFAR4 (0.68) | NR3C1HTTKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL21180007 | 0.76 | KEAP1 (0.53) | NR3C1KDM4EHSD17B10KEAP1NFE2L2 | |
| SCHEMBL29788171 | 0.76 | EGFR (0.49) | KDM4ESMN1; SMN2HSD17B10PTPRCPTPRF | |
| SCHEMBL2038076 | 0.76 | EGFR (0.49) | KDM4ESMN1; SMN2HSD17B10PTPRCPTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2019-07-23 | — | — | US | disclosed |
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2018-10-18 | — | — | US | disclosed |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2017-10-05 | — | — | US | disclosed |
| EP-2513053-B1 | Pyrrolidine carboxylic acid derivatives as agonists of G-protein coupled receptor 43 (GPR43), pharmaceutical composition and methods for use in treating metabolic disorders | OGEDA SA (BE) | 2017-10-04 | — | — | EP | disclosed |
| US-9770435-B2 | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | OGEDA SA (BE) | 2017-09-26 | — | — | US | disclosed |
| US-9695120-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | OGEDA SA (BE) | 2017-07-04 | — | — | US | disclosed |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3074008-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | Euroscreen S.A. (BE) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015078949-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN SA (BE) | 2015-06-04 | — | — | WO | disclosed |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| EP-2513053-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | Euroscreen S.A. (BE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073376-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43) | EUROSCREEN S.A. (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297944-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | NR3C1 193/4885HTT 2689/4885KDM4E 4211/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | NR3C1 193/4885HTT 2689/4885KDM4E 4211/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | NR3C1 193/4885HTT 2689/4885KDM4E 4211/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | NR3C1 221/4885HTT 1655/4885KDM4E 4299/4885 |
| US-10358416-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GIPR, GPR88, GPR119 | NR3C1 495/4885HTT 1846/4885KDM4E 3994/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | NR3C1 193/4885HTT 2689/4885KDM4E 4211/4885 |
| US-20130023539-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | NR3C1 221/4885HTT 1655/4885KDM4E 4299/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | NR3C1 234/4885HTT 2412/4885KDM4E 3833/4885 |
| US-20160303075-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | PTGS1, PTGES, PTGER1 | NR3C1 286/4885HTT 1673/4885KDM4E 4591/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | NR3C1 191/4885HTT 2690/4885KDM4E 4160/4885 |
| US-20170283376-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | NR3C1 193/4885HTT 2689/4885KDM4E 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.